1. Tadalafil versus pentoxifylline in the management of diabetic kidney disease: a randomized clinical trial
- Author
-
Sahar Kamal Hegazy, Walaa Ahmed Amaar, and Wafaa Salah Mohamed Hegab
- Subjects
Diabetic kidney disease ,Hemoglobin A1C ,Pentoxifylline ,Tadalafil ,Urinary Albumin/Creatinine ratio ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Aims To investigate the efficacy and safety of tadalafil (TAD) versus pentoxifylline (PTX) in the management of diabetic kidney disease (DKD). Some animal studies and clinical trials reported that tadalafil and pentoxifylline have a reducing effect on different blood glucose parameters and lipid profiles which contribute to progress the patients with diabetes mellitus (DM) to DKD. Methods From February 2022 to March 2023, 90 patients with type 2 DM and DKD (micro-albuminuria) were enrolled in this randomized-controlled study. The patients were randomized into three equal groups: control group, TAD group, and PTX group. The three groups received traditional blood glucose lowering therapy + ramipril 10 mg PO. The TAD group also received tadalafil 20 mg PO every other day. The PTX group also received pentoxifylline 400 mg PO twice daily. Results Both TAD and PTX groups produced statistically significant improvement in the primary outcomes by a significant reduction in Urinary albumin/creatinine ratio (UACR) which was pronounced by a reduction percentage of—47.47%, −53.73% respectively. In addition to a significant decrease in Hemoglobin A1C (HbA1c) (mmol/mol), Fasting blood glucose (FBG), 2-h postprandial blood glucose (2-h PPG) (p
- Published
- 2024
- Full Text
- View/download PDF